Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH

Treatment of Nonalcoholic fatty liver disease (NAFLD) constitutes an unmet clinical need owing to the relatively limited efficacy of both novel and readily available metabolic medications, thus warranting pathobiological investigations on the mechanisms of single or combination regimens. In this con...

Descripción completa

Detalles Bibliográficos
Autores principales: Perakakis, Nikolaos, Stefanakis, Konstantinos, Feigh, Michael, Veidal, Sanne S, Mantzoros, Christos S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Cardiovascular Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089912/
http://dx.doi.org/10.1210/jendso/bvab048.642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089912/
http://dx.doi.org/10.1210/jendso/bvab048.642

Ejemplares similares